Ascendis Pharma A/S (ASND) : Fridays money flow data in Ascendis Pharma A/S (ASND) suggests that the bulls made the most of the weakness in the stock. The inflow of money into the stock on upticks was $2.35 million, whereas, $0.38 million worth of transactions were done on downticks. The ratio between the two, uptick and downtick stood at 6.25, in favor of the bulls. The total money flow into the stock was $1.97 million clearly indicating that the smart money has been buying into the stock on weakness.
In comparison, the money flow in block deals was $1.96 million. The total value of block trades done on upticks was $1.96 million. Ascendis Pharma A/S (ASND) fell $0.24 and traded at $19.4, down -1.22% for the day, over previous days close. On a weekly basis, the shares are 9.79% over the previous weeks close.
Institutional Investors own 58.23% of Ascendis Pharma A/S shares.
Ascendis Pharma A/S (NASDAQ:ASND): stock was range-bound between the intraday low of $19.01 and the intraday high of $19.89 after having opened at $19.89 on Fridays session. The stock finally closed in the red at $19.89, a loss of -1.22%. The stock remained in the red for the whole trading day. The total traded volume was 163,669 shares. The stock failed to cross $19.89 in Fridays trading. The stocks closing price on Thursday was $19.64.
Ascendis Pharma A/S (ASND) : Traders are bullish on Ascendis Pharma A/S (ASND) as it has outperformed the S&P 500 by a wide margin of 34.43% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 9.24%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 9.79% in the last 1 week, and is up 34.26% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Ascendis Pharma A/S is a clinical stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its lead product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Insulin for the treatment of diabetes, TransCon Peptide for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology.